Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | IMVT |
---|---|---|
09:32 ET | 4143 | 26.87 |
09:34 ET | 6747 | 27.14 |
09:36 ET | 700 | 27.07 |
09:38 ET | 2945 | 27.39 |
09:39 ET | 1650 | 27.39 |
09:41 ET | 725 | 27.33 |
09:43 ET | 1100 | 27.22 |
09:45 ET | 400 | 27.0991 |
09:48 ET | 3700 | 27.29 |
09:50 ET | 200 | 27.24 |
09:52 ET | 5028 | 27.105 |
09:56 ET | 4363 | 27.32 |
09:57 ET | 400 | 27.25 |
09:59 ET | 800 | 27.35 |
10:01 ET | 1745 | 27.28 |
10:03 ET | 1300 | 27.25 |
10:06 ET | 11142 | 27.245 |
10:08 ET | 1979 | 27.26 |
10:10 ET | 1300 | 27.225 |
10:12 ET | 400 | 27.28 |
10:14 ET | 700 | 27.27 |
10:15 ET | 6237 | 27.254 |
10:17 ET | 200 | 27.23 |
10:19 ET | 4196 | 27.27 |
10:21 ET | 1585 | 27.31 |
10:24 ET | 2476 | 27.31 |
10:26 ET | 1457 | 27.36 |
10:28 ET | 1394 | 27.29 |
10:30 ET | 1355 | 27.27 |
10:32 ET | 1666 | 27.26 |
10:33 ET | 2423 | 27.3 |
10:35 ET | 277 | 27.3 |
10:37 ET | 7440 | 27.23 |
10:39 ET | 1000 | 27.29 |
10:42 ET | 1592 | 27.29 |
10:44 ET | 800 | 27.27 |
10:46 ET | 1623 | 27.26 |
10:48 ET | 1100 | 27.26 |
10:50 ET | 534 | 27.26 |
10:51 ET | 900 | 27.26 |
10:53 ET | 1600 | 27.31 |
10:55 ET | 4960 | 27.335 |
10:57 ET | 1879 | 27.335 |
11:00 ET | 633 | 27.32 |
11:02 ET | 2767 | 27.32 |
11:04 ET | 2100 | 27.22 |
11:08 ET | 777 | 27.095 |
11:09 ET | 636 | 27.095 |
11:11 ET | 100 | 27.06 |
11:13 ET | 1800 | 26.94 |
11:15 ET | 1300 | 26.97 |
11:20 ET | 700 | 26.95 |
11:22 ET | 454 | 26.93 |
11:24 ET | 2106 | 26.9 |
11:26 ET | 936 | 26.9 |
11:27 ET | 4024 | 26.96 |
11:31 ET | 100 | 26.98 |
11:33 ET | 2618 | 26.92 |
11:36 ET | 721 | 26.91 |
11:38 ET | 610 | 26.93 |
11:40 ET | 2089 | 26.855 |
11:42 ET | 303 | 26.83 |
11:44 ET | 2809 | 26.79 |
11:45 ET | 842 | 26.85 |
11:49 ET | 200 | 26.82 |
11:51 ET | 300 | 26.79 |
11:54 ET | 100 | 26.81 |
11:56 ET | 1550 | 26.9 |
11:58 ET | 3800 | 26.93 |
12:00 ET | 1070 | 26.94 |
12:03 ET | 1205 | 26.93 |
12:05 ET | 3200 | 26.965 |
12:07 ET | 6465 | 27.07 |
12:09 ET | 2342 | 27.035 |
12:12 ET | 1046 | 27.06 |
12:16 ET | 1000 | 27.14 |
12:18 ET | 1658 | 27.18 |
12:20 ET | 100 | 27.16 |
12:21 ET | 2247 | 27.22 |
12:23 ET | 1500 | 27.19 |
12:27 ET | 1506 | 27.19 |
12:30 ET | 4000 | 27.2 |
12:32 ET | 11698 | 27.303 |
12:34 ET | 1700 | 27.33 |
12:36 ET | 1000 | 27.3 |
12:38 ET | 1986 | 27.31 |
12:39 ET | 300 | 27.29 |
12:41 ET | 1632 | 27.29 |
12:43 ET | 6726 | 27.43 |
12:45 ET | 613 | 27.41 |
12:48 ET | 600 | 27.39 |
12:50 ET | 2044 | 27.46 |
12:52 ET | 1300 | 27.49 |
12:54 ET | 100 | 27.47 |
12:56 ET | 13365 | 27.52 |
12:57 ET | 100 | 27.53 |
12:59 ET | 1000 | 27.42 |
01:01 ET | 300 | 27.39 |
01:03 ET | 600 | 27.38 |
01:06 ET | 1000 | 27.3 |
01:08 ET | 629 | 27.37 |
01:10 ET | 100 | 27.4 |
01:12 ET | 2410 | 27.37 |
01:14 ET | 200 | 27.375 |
01:15 ET | 400 | 27.36 |
01:17 ET | 350 | 27.37 |
01:19 ET | 3385 | 27.36 |
01:21 ET | 700 | 27.32 |
01:26 ET | 400 | 27.29 |
01:28 ET | 775 | 27.28 |
01:30 ET | 2200 | 27.315 |
01:32 ET | 500 | 27.29 |
01:33 ET | 200 | 27.295 |
01:35 ET | 1900 | 27.23 |
01:37 ET | 100 | 27.225 |
01:39 ET | 1950 | 27.235 |
01:42 ET | 730 | 27.22 |
01:44 ET | 1694 | 27.23 |
01:48 ET | 300 | 27.22 |
01:50 ET | 10400 | 27.24 |
01:51 ET | 100 | 27.215 |
01:53 ET | 1234 | 27.34 |
01:55 ET | 804 | 27.29 |
01:57 ET | 755 | 27.33 |
02:00 ET | 200 | 27.3 |
02:02 ET | 700 | 27.32 |
02:04 ET | 600 | 27.365 |
02:06 ET | 300 | 27.36 |
02:08 ET | 1400 | 27.43 |
02:09 ET | 1200 | 27.4 |
02:11 ET | 400 | 27.41 |
02:13 ET | 300 | 27.425 |
02:15 ET | 1900 | 27.415 |
02:18 ET | 800 | 27.43 |
02:20 ET | 2477 | 27.465 |
02:22 ET | 700 | 27.43 |
02:24 ET | 1988 | 27.53 |
02:26 ET | 1000 | 27.49 |
02:27 ET | 1600 | 27.47 |
02:29 ET | 1099 | 27.47 |
02:31 ET | 3329 | 27.565 |
02:33 ET | 2815 | 27.62 |
02:36 ET | 1115 | 27.615 |
02:38 ET | 1650 | 27.59 |
02:40 ET | 2120 | 27.585 |
02:42 ET | 1100 | 27.615 |
02:44 ET | 2945 | 27.629 |
02:45 ET | 1202 | 27.58 |
02:47 ET | 2364 | 27.68 |
02:49 ET | 4300 | 27.7999 |
02:51 ET | 1448 | 27.805 |
02:54 ET | 6291 | 27.74 |
02:56 ET | 3535 | 27.75 |
02:58 ET | 1349 | 27.78 |
03:00 ET | 3468 | 27.77 |
03:02 ET | 400 | 27.77 |
03:03 ET | 1894 | 27.79 |
03:05 ET | 1414 | 27.77 |
03:07 ET | 1705 | 27.72 |
03:09 ET | 529 | 27.66 |
03:12 ET | 2130 | 27.695 |
03:14 ET | 7578 | 27.7 |
03:16 ET | 3300 | 27.695 |
03:18 ET | 1500 | 27.7 |
03:20 ET | 1820 | 27.708 |
03:21 ET | 1200 | 27.69 |
03:23 ET | 3659 | 27.71 |
03:25 ET | 1523 | 27.67 |
03:27 ET | 1398 | 27.645 |
03:30 ET | 8034 | 27.66 |
03:32 ET | 2307 | 27.69 |
03:34 ET | 2294 | 27.63 |
03:36 ET | 3300 | 27.62 |
03:38 ET | 2271 | 27.6025 |
03:39 ET | 3919 | 27.56 |
03:41 ET | 1870 | 27.51 |
03:43 ET | 3794 | 27.62 |
03:45 ET | 2079 | 27.57 |
03:48 ET | 2043 | 27.59 |
03:50 ET | 5450 | 27.61 |
03:52 ET | 4171 | 27.645 |
03:54 ET | 5300 | 27.61 |
03:56 ET | 9178 | 27.62 |
03:57 ET | 10508 | 27.63 |
03:59 ET | 95781 | 27.65 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Immunovant Inc | 3.9B | -14.7x | --- |
Avidity Biosciences Inc | 4.1B | -13.1x | --- |
Immunitybio Inc | 4.4B | -6.3x | --- |
Crinetics Pharmaceuticals Inc | 3.5B | -12.0x | --- |
Dyne Therapeutics Inc | 3.4B | -8.5x | --- |
Merus NV | 3.6B | -20.5x | --- |
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 146.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.89 |
Book Value | $4.24 |
P/E Ratio | -14.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.